Stay updated with breaking news from Positive Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine Results published today in the New England Journal of
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and seco...
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking...
Positive Phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session Dupixent significantly improved skin